GlobeNewswire by notified

Roche Annual General Meeting 2020

Share
  • All proposals of the Board of Directors approved
  • Christoph Franz confirmed as Chairman of the Roche Board of Directors; all other Board members standing for re-election confirmed; Jörg Duschmalé and Patrick Frost elected as new members of the Board of Directors
  • Andreas Oeri and Sir John Bell step down from the Board of Directors after 24 and 19 years, respectively
  • 33rd consecutive dividend increase to CHF 9.00 per share

Basel, 17 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM).
On the basis of COVID-19 Ordinance 2 of the Swiss Federal Council, no shareholders were admitted to attend the General Meeting in person. Roche had already recommended on March 10 that shareholders should delegate their votes to the independent proxy. The independent proxy represented 85.47 % of the total 160,000,000 shares. The Management Report, the Financial Statements and the Consolidated Financial Statements for 2019 were approved.

Shareholders endorsed the total amount of bonuses paid to the Corporate Executive Committee for 2019 with 99.69 % of the votes, as well as the bonus paid to the Chairman of the Board of Directors for 2019, which was approved by 99.03 % of the votes. Shareholders also authorised the ratification of the Board of Directors’ actions.

Shareholders approved the proposed appropriation of available earnings with 100 % of the votes and approved an increase in the dividend for the past financial year to 9.00 Swiss francs (gross) per share and non-voting equity security. This is the 33rd consecutive dividend increase.
Christoph Franz was confirmed as Chairman of the Board of Directors with 99.52% of the votes.

“2019 was a very good year for Roche. We made further significant progress in renewing our product portfolio. The new medicines are not only driving sales for Roche, they are also making substantial contributions to improving the lives of patients worldwide. The acquisition of Spark Therapeutics adds gene therapy to our portfolio of therapeutic approaches,” said Christoph Franz, Chairman of Roche's Board of Directors. “I am confident that we are well positioned for the future by virtue of our broad portfolio and innovative strength, and that we will continue to make important contributions to the health of people throughout the world.”

Andreas Oeri is stepping down from the Board of Directors after 24 years as the representative of the current shareholder pool. He will be succeeded by Jörg Duschmalé, who is joining the Board as a fifth-generation descendant of the company’s founder. Patrick Frost was also elected to the Board alongside Jörg Duschmalé.

“I would like to thank Andreas Oeri for his huge personal contribution and tireless dedication to Roche’s success. The fact that Roche is now one of the most sustainable healthcare companies in the world is in no small part due to him. Jörg Duschmalé's election is once again an impressive reaffirmation of commitment and long-term perspective by the owning families into this company.
Sir John Bell’s great scientific expertise made him practically indispensable during the development of Roche over the past two decades. On behalf of the entire Board, I would like to thank him sincerely.
I wish Andreas Oeri and Sir John Bell all the best for the future. I warmly welcome Jörg Duschmalé and Patrick Frost to the Board and am very much looking forward to working with them,” said Christoph Franz

In addition to Christoph Franz, Jörg Duschmalé and Patrick Frost, all other Board members who stood for re-election were confirmed for a term of one year:

  • André Hoffmann
  • Julie Brown
  • Paul Bulcke
  • Professor Hans Clevers
  • Anita Hauser
  • Professor Richard P. Lifton
  • Bernard Poussot
  • Dr Severin Schwan
  • Dr Claudia Süssmuth Dyckerhoff

The following Board members were elected to the Remuneration Committee:

  • Dr Christoph Franz
  • André Hoffmann
  • Professor Richard P. Lifton
  • Bernard Poussot

Shareholders also approved the maximum total amount of future remuneration of the Board of Directors, which was confirmed by 99.66 % of the votes, and the maximum total amount of future remuneration for the Corporate Executive Committee until the 2021 ordinary Annual General Meeting by 99.66 % of the votes.

The Meeting elected Testaris AG as independent proxy for the 2020 financial year until the conclusion of the 2021 ordinary Annual General Meeting and KPMG AG as external auditor for the financial year 2020.


About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.



Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
- Nicolas Dunant (Head)
- Patrick Barth
- Daniel Grotzky
- Karsten Kleine
- Nathalie Meetz
- Barbara von Schnurbein

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye